After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.